The short version of receptor targets fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
The complaint further alleged that the injections caused a permanent loss of mobility and function from which she never recovered, describing the use of the drug as a form of "chemical restraint" and outside the standard of care. The case highlights concerns about the off-label use of antipsychotics in elderly dementia patients, a practice for which the drug carries a black box warning from the FDA due to an increased risk of death. Billy Driver, Jr. is a California prisoner who has been involuntarily administered the long-acting injectable antipsychotic Invega Sustenna (paliperidone palmitate) since at least 2019. He has filed multiple federal civil rights lawsuits alleging the forced medication causes severe side effects, including gynecomastia, borderline diabetes, heart palpitations, chest pain, and kidney pain. In one suit, Driver v. Naranjo (filed January 2024), Driver alleged that psychiatrist Dr. Naranjo at the Richard J. Donovan Correctional Facility (RJD) in San Diego had twice threatened to use physical force if Driver continued to refuse the injections. A judge dismissed Driver v. Naranjo in February 2025, noting that Driver's involuntary medication was authorized by active court orders issued through California's Keyhea process. Since 2020, Driver has undergone six Keyhea hearings, at each of which a court found that if unmedicated he would be a danger to others, that he lacked insight into his own need for medication, and that he could not manage his own treatment.
=== Philanthropy === Morea serves as the captain and midfielder of the All Stars Football Club, a celebrity football team that participates in matches to raise funds for charitable causes. He played in a high-profile charity cricket match organized by the IIFA Foundation at Headingley Carnegie Stadium in Leeds, England, on 8 June 2007. The event featured a star-studded Indian celebrity team—including Virat Kohli, Kapil Dev, Vivek Oberoi, Ajay Devgn, Shilpa Shetty, Sunny Deol, and many others—competing against a UK celebrity team and the match benefited the IIFA Foundation's charitable causes. Morea attended a charity football match for the Salman Khan's Being Human Foundation in Mumbai on 15 August 2009. Dino joined Salman Khan, Aamir Khan, Amitabh Bachchan, and others for a blood donation camp in Bandra, Mumbai on 15 August 2010. In March 2013, he participated in a match to support the Magic Funds Organisation, which works with underprivileged children. In 2016, he became associated with Pet Fed, an event platform for pets, joining as an investor and supporter.
Across several benchmarks, AlphaFold3 has demonstrated, on average, superior performance to conventional search-based docking algorithms in predicting small-molecule–protein binding modes. AlphaFold 3 version can predict structures of protein complexes with a very limited set of selected cofactors and co- and post-translational modifications. Between 50% and 70% of the structures of the human proteome are incomplete without covalently-attached glycans. Studies have shown that although AlphaFold3 can jointly model protein–ligand co-folding, its accuracy drops markedly on test cases with low similarity to its training data—an area of particular importance for drug discovery. Other work has found that AlphaFold is insensitive to adversarial decoys generated by altering the physicochemical properties of binding pockets, suggesting potential reliance on training-set memorization rather than genuine chemical awareness.
Sources: en.wikipedia.org
== Other activities == Guillaume and his wife Donna were co-founders of Artists for a Free South Africa (later renamed Artists for a New South Africa) in 1989, along with a number of other Hollywood actors, including Alfre Woodard.
Desomorphine (or in some formulations known as Krokodil) is a semi-synthetic opioid commercialized by Roche, with powerful, fast-acting effects, such as sedation and analgesia. It was first discovered and patented in Germany by a German team working for Knoll in 1920 but was not generally recognized. It was later synthesized in 1932 by American chemist Lyndon Frederick Small. Small also successfully patented it in 1934 in the United States. Desomorphine was used in Germany, Austria, and Switzerland under the brand name Permonid and was described as having a fast onset and a short duration of action, with relatively little nausea compared to equivalent doses of morphine. Dose for dose it is roughly ten times more potent than morphine, with 1 mg desomorphine being equivalent 10 mg morphine, via the intravenous (IV) or intramuscular (IM) routes. Desomorphine is a morphine analogue where the 6-hydroxyl group and the 7,8 double bond have been reduced. The traditional synthesis of desomorphine starts from α-chlorocodide, which is itself obtained by treating codeine with thionyl chloride. By catalytic reduction, α-chlorocodide gives dihydrodesoxycodeine, which yields desomorphine on demethylation. A desomorphine product, usually based on codeine, has been developed as a recreational drug. The product in question is typically a highly impure variant of desomorphine. The scaly sores and necrosis that develop around the injection site has prompted the name krokodil (Russian for crocodile).
== Early career, Minister of Finance, and first presidential run (1999–2018) == Peña joined the Industrial Development Fund as an analyst in 1999 and served as an economist at the Central Bank of Paraguay from 2000 to 2009. He was appointed as one of the four directors of the Central Bank of Paraguay in 2012, leaving his job at the IMF.
Sources: en.wikipedia.org
Shulman (1943), biophysicist, Sterling Professor emeritus at Yale University Seymour Jonathan Singer (1943), cell biologist and professor at the University of California, San Diego Enoch Callaway (1943), psychiatrist, professor at the University of California, San Francisco Arnold Cooper (1944), psychoanalyst; professor at Weill Cornell Medical College and former president of the American Psychoanalytic Association Robert Jastrow (1944), astronomer, founder of NASA's Goddard Institute for Space Studies and conservative think tank George C. Marshall Institute Joshua Lederberg (1944), winner of the Nobel Prize in Physiology or Medicine Arnold Scheibel (1944), professor of neuroscience at the University of California, Los Angeles Alfred P. Wolf (1944), nuclear and organic chemist; research professor at New York University Paul Marks (1945), geneticist, president emeritus of the Memorial Sloan Kettering Cancer Center, former editor-in-chief of the Journal of Clinical Investigation Jack Oliver (1945), professor of seismology at Columbia University and Cornell University Malvin Ruderman (1945), physicist known for discovering the RKKY interaction Leonard Shengold (1946), psychiatrist at New York University known for study on child abuse Albert Starr (1946), cardiovascular surgeon, winner of the 2007 Lasker Award Arthur Ashkin (1947), winner of the Nobel Prize in Physics in 2018 Robert A. Frosch (1947), fifth administrator of the National Aeronautics and Space Administration Norton Zinder (1947), scientist who discovered bacterial transduction Frank I.
=== Extracellular matrix === Extracellular matrix (or "ECM") is the external structural framework that cells attach to in multicellular organisms. The dermis lies below the epidermis, and these two layers are collectively known as the skin. Dermal skin is primarily a combination of fibroblasts growing in this matrix. The specific species of ECM of connective tissues often differ chemically, but collagen generally forms the bulk of the structure. Through the interaction of a cell with its extracellular matrix (transmitted through the anchoring molecules classed as integrins) there forms a continuous association between the cell interior, cell membrane and its extracellular matrix components that helps drive various cellular events in a regulated fashion. Wound healing is a localized event involving the reaction of cells to the damage sustained. The cells break down damaged ECM and replace it, generally increasing in number to react to the harm. The process is activated, though perhaps not exclusively, by cells responding to fragments of damaged ECM, and the repairs are made by reassembling the matrix by cells growing on and through it. Because of this, extracellular matrix is often considered as a 'conductor of the wound healing symphony'. In the Inflammatory phase, neutrophils and macrophages recruit and activate fibroblasts which in subsequent granulation phase migrate into the wound, laying down new collagen of the subtypes I and III. In the initial events of wound healing, collagen III predominates in the granulation tissue.
== See also == Fleet telematics Fleet tracking GPS tracking National Association of Fleet Administrators (NAFA) Satellite tracking Telematics Vehicle remarketing Vehicle tracking system Fleet management software
== Bioencapsulations == Alginate is one of the most widely used polymers in bioencapsulation, particularly for the immobilisation or protection of living cells, enzymes, proteins and other bioactive materials. Its use is largely based on the ability of soluble alginate to form calcium alginate hydrogels under mild aqueous conditions, allowing biological material to be entrapped without exposure to harsh solvents, high temperature or aggressive chemical reactions. In cell encapsulation, alginate beads or microcapsules can provide a semipermeable hydrogel matrix that permits diffusion of nutrients, oxygen and secreted products while physically separating the encapsulated cells from the surrounding environment. This approach has been investigated for immunoisolation, islet transplantation, cell therapy, tissue engineering and controlled delivery of biological products. Alginate bioencapsulation systems can be produced by dripping, extrusion, air-jet cutting, electrostatic droplet generation, emulsification and microfluidic methods. These techniques differ in throughput, bead-size control, size distribution and suitability for encapsulating cells or labile biomolecules.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.